LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Lab-on-Paper Developed for Rapid Inexpensive Medical Diagnostics

By LabMedica International staff writers
Posted on 15 Mar 2015
Print article
Image: Schematics of the unique fluid transport property of the platform is demonstrated in the figure using dye-containing fluids (Photo courtesy of Labonachip LLC).
Image: Schematics of the unique fluid transport property of the platform is demonstrated in the figure using dye-containing fluids (Photo courtesy of Labonachip LLC).
A new paper-based platform has been created for conducting a wide range of complex medical diagnostics including Lyme disease, human immunodeficiency virus, Ebolavirus disease and malaria.

The key development was the invention of fluid actuated valves embedded in the paper that allow for sequential manipulation of sample fluids and multiple reagents in a controlled manner to perform complex multistep immune-detection tests without human intervention.

A team of engineers at the University of Rhode Island (URI; Kingston, RI, USA) used the principle of paper-based lateral flow test strips where sample fluid wicks along a strip of paper, reacts with embedded reagents, and produces a colored signal result. However, more complex medical diagnostics such as enzymatic assay protocols require multiple reagents triggered at particular times during the process, which can only be accomplished autonomously using the proprietary microfluidic valve technology created by the engineers.

The lab-on-paper devices are constructed with multiple layers of paper printed with wax to create a three-dimensional structure of valves and channels along which the fluid travels, triggering the reagents at the appropriate time and generating a result. This new paper-based technology is the next generation of the lab-on-a-chip device the team reported in 2011, which has been further refined since then. That device is now smaller and employs an innovative micropump for precise fluid movement within the cartridge's microchannels.

The scientists have already succeeded in performing a feasibility study of their technology by detecting a biomarker for sepsis, a life-threatening complication from an infection. ProThera Biologics (East Providence, RI, USA) identified a biomarker that indicates a patient is going into shock from sepsis, and the company has collaborated with the URI engineers to develop a paper-based rapid test using this biomarker, and have established a startup company, Labonachip LLC (North Kingstown, RI, USA) to commercialize their technologies.

Mohammad Faghri, PhD, a professor of Mechanical Engineering and Applied Mechanics, and inventor of the platform said, “We combined the well-established test strip technology, micro-patterning techniques and our innovative paper-based valves to create a new class of strip tests that are capable of autonomously handling multiple reagents. The sample fluid activates the flow of reagents in a predetermined sequence and time. When combined with an optical reader, which could even be a conventional smart phone, the lab-on-paper device provides accurate quantitative results.”

Related Links:

University of Rhode Island
ProThera Biologics
Labonachip LLC


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more